| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net income | -5.6 | -5.1 |
| EPS (diluted, $ a share) | $-0.68 | $-0.98 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: BIVI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Biovie Inc.: key numbers
- Share price
- $0.9953Close, Nov 17
- Market cap
- $10.7M
- Shares outstanding
- 10.72MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Biovie Inc.
All →Biovie Shareholder Meeting
BioVie Inc. held its 2026 Annual Meeting of Stockholders where shareholders elected six directors to the board and ratified EisnerAmper LLP as the independent auditor for fiscal 2027. Shareholders also approved an amendment to the 2019 Omnibus Equity Incentive Plan, significantly increasing the share pool from 399,509 to 3,100,000 shares.
Biovie Capital Raise of $4.74M
BioVie Inc. entered into a securities purchase agreement with an institutional investor for a $4.74 million registered direct offering and concurrent private placement. The company issued 960,000 shares and 2,002,500 pre-funded warrants at $1.60 per share/equivalent, along with 2,962,500 common warrants. Proceeds are intended for working capital and general corporate purposes.
- Value
- $4.74M
Biovie Other 8-K Filing
BioVie Inc. entered into a sales agreement with A.G.P./Alliance Global Partners to establish an at-the-market (ATM) offering program. Under the agreement, the company may issue and sell shares of its Class A common stock having an aggregate offering price of up to approximately $6.46 million from time to time. The company has no obligation to sell any shares and intends to use any potential proceeds for general corporate purposes.
- Counterparty
- A.G.P./Alliance Global Partners